TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04970719
Drug: Remdesivir
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 5-day total course
Study: NCT05219838
Drug: Lu AG06466
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu AG06466 will be administered per dose and schedule specified in the arm description.
Study: NCT04994704
Drug: Remimazolam group
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam group will be started total intravenous anesthesia with remiamazolam at 6 mg/kg/h for induction, and maintained at 0.5-1.5 mg/kg/h and remifentanil under TCI model.
Study: NCT05442450
Drug: oral semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants in Experimental group will receive oral Semaglutide along with diet and exercise. Treatment will be initiated with the 3 mg once-daily dose. The dose will be increased to 7 mg and then maximum of 14mg per day in 2-4weeks interval based on patient tolerance.
Study: NCT04969705
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 Patients will be randomly divided into three equal groups:~Group A (n=20) : spinal anesthesia with Dexmedetomidine (5µg ) added to local anesthetic (bupivacaine Hcl ) (10 mg) given intrathecally .~Group B (n=20) : spinal anesthesia using local anesthetic( bupivacaine Hcl) (20 mg) combined with TAP block using Dexmedetomidine (20µg ) after the cesarean section~Group C (n=20) (controlled group ) : Spinal anesthesia using only local anesthetic (bupivacaine Hcl ) (10 mg) .
Study: NCT06349122
Drug: Azithromycine
Normalized name: Azithromycine
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In case of Chlamydia trachomatis infections, as well as significant increase of Fannyhessea vaginae: 1 g per os in a single dose; In case of Neisseria gonorrhoeae infection: 2 g per os in a single dose (associated to ceftriaxone 1g IM)
Study: NCT06349122
Drug: Ceftriaxone
Normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In case of Neisseria gonorrhoeae infections, 1g, associated to azithromycin 2 g per os in a single dose
Study: NCT06349122
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole ovules: In case of Trichomonas vaginalis infection during the 1st trimester of pregnancy: 1 ovule morning and evening for 14 days (French Society of Dermatology Recommendations 2016); Metronidazole 500 mg tablets in case of Trichomonas vaginalis infection during the 2nd or the 3rd trimester of pregnancy in a single dose of 2 g
Study: NCT06349122
Drug: Clotrimazole, Vaginal
Normalized name: Clotrimazole, Vaginal
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In case of Candida albicans infection in a single dose to be repeated up to 6 times if necessary.
Study: NCT04967625
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A humanized anti-PD-1 monoclonal antibody
Study: NCT04967625
Drug: Anlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A tyrosine kinase inhibitor selectively targeting VEGFR-2
Study: NCT04570345
Drug: ticagrelor monotherapy
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: • Drug: ticagrelor monothearpy after first 3 months dual therapy
Study: NCT04570345
Drug: Aspirin with P2Y12 receptor inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: • Drug: aspirin plus ticagrelor dual therapy during 12 months
Study: NCT05100719
Drug: alverine-citrate + simethicone and lactase
Normalized name: alverine citrate
DrugBank: Alverine (DB01616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who randomized in the first arm are treated with alverine-citrate + simethicone and lactase.
Study: NCT05100719
Drug: alverin-citrate + simethicone with placebo
Normalized name: alverine citrate
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the second arm receive alverin-citrate + simethicone with placebo without lactase.
Study: NCT06543563
Drug: esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After the craniotomy, a continuous infusion of ketamine at a rate of 0.3 mg/kg/h (0.3 ml/kg/h) is administered until the completion of electrode implantation, prior to microelectrode recording (MER) and electrode insertion. After the administration of the drug, close monitoring of the patient's blood pressure and heart rate is conducted to maintain circulatory stability.
Study: NCT05777109
Drug: HS-20090
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A human IgG2 monoclonal antibody with affinity and specificity for human RANKL
Study: NCT06445400
Drug: BL-M07D1
Normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT06445400
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT06445400
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT06151210
Drug: DA-5219
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet/day
Study: NCT04878016
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin should be administered after completion of placebo/ZKAB001 by IV infusion over 30-60 minutes to achieve an initial target AUC of 5 mg/mL/min. Carboplatin and etoposide will be used for a total of 4 cycles， followed by placebo/ZKAB001 maintenance therapy.
Study: NCT04878016
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide (100 mg/m\^2) should be administered intravenously over 60 minutes following carboplatin administration. On Days 2 and 3 of each cycle, etoposide 100 mg/m2) should be administered intravenously over 60 minutes.~Carboplatin and etoposide will be used for a total of 4 cycles， followed by placebo/ZKAB001 maintenance therapy.
Study: NCT00178451
Drug: Abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05736419
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PK-guided fludarabine dosing will be used for each of the 2 cycles, using the InsightRx DoseMeRx platform.
Study: NCT05736419
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus will be administered beginning on day +5
Study: NCT05736419
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) will be administered three times daily starting on day +5.
Study: NCT05736419
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard Regimen: Dexamethasone on days -68 to -64 and days -40 to -36.
Study: NCT05736419
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib on days -71, -68, -65, -61, -43, -40, -37, and -33
Study: NCT05736419
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab on days -71, -58, -43, and -30.
Study: NCT06387628
Drug: LM-108
Normalized name: LM-030
DrugBank: LM-030 (DB18283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LM-108, 10mg/kg, d1, q6w
Study: NCT06387628
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab, 240 mg, d1, q3w
Study: NCT06387628
Drug: Eribulin
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin 1.4 mg/m2, d1, 8 , q3w
Study: NCT06387628
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab paclitaxel 125 mg/m2, d1, 8 , q3w
Study: NCT04696393
Drug: Mitapivat tablet
Normalized name: Mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT06471712
Drug: 18F-LNC1007 Injection
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy volunteers will receive 1 MBq/kg and cancer patients will receive 3.7 MBq/kg. The injection will be carried out on the scan bed via an IV indwelling catheter. A 10 mL normal saline flush will be given after the completion of the injection to ensure the residue is injected.
Study: NCT06546540
Drug: Telitacicept
Normalized name: Telitacicept
DrugBank: Telitacicept (DB18312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160mg，once weekly
Study: NCT00513201
Drug: lyspro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06130072
Drug: iso-amyl- 2-cyanoacrylate.
DrugBank: Amyl acetate (DB15927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hysteroscopic tubal occlusion using iso-amyl- 2-cyanoacrylate in patients with hydrosalpinx prior to IVF
Study: NCT06130072
Drug: iso-amyl- 2-cyanoacrylate mixed with Ethiodized oil
Normalized name: OCTYL-2-CYANOACRYLATE
DrugBank: Ethiodized oil (DB00965)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iso-amyl- 2-cyanoacrylate mixed with Ethiodized oil (Lipidol)
Study: NCT05828758
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 10 mg/kg (50 mg/ml concentration) by nasogastric tube 3 times daily (8 hours apart) 10 minutes before bolus gastric feeding for 7 days.
Study: NCT04803747
Drug: Tranexamic acid (TXA)
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TXA 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).
Study: NCT04803747
Drug: Placebo (0.9 % Saline)
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo (0.9 % normal saline) 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).
Study: NCT04893525
Drug: Buprenorphine/naloxone
Normalized name: BUPRENORPHINE/NALOXONE
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine/naloxone is a first line, evidence-based opioid agonist therapy that improves mortality for people with opioid use disorder, and that has been demonstrated to be effective at retaining people in addictions care and decreasing illicit opioid use when initiated from EDs.
Study: NCT04731259
Drug: ATR-04
Normalized name: Atr-101 free base
DrugBank: Nevanimibe (DB16254)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATR-04 is a proprietary formulated product containing lyophilized SEΔΔΔ, a Staphylococcus epidermidis genetically modified to be auxotrophic to D-alanine as the active ingredient.
Study: NCT05478382
Drug: Pregabalin 25 MG
Normalized name: pregabalin 25 MG
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients are given 0 to 3 capsules per administration according to their allocated group.
Study: NCT04603742
Drug: Anakinra
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100 mg of Anakinra will be mixed with 100 mL of 0.9% saline solution for IV administration.
Study: NCT04924140
Drug: Aducanumab
Normalized name: Aducanumab
DrugBank: Aducanumab (DB12274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT05372887
Drug: TNX-102 SL
Normalized name: TNX-901
DrugBank: TNX-901 (DB05797)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks
Study: NCT05625932
Drug: Tinzaparin
Normalized name: Tinzaparin
DrugBank: Tinzaparin (DB06822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients \< 80 kg will receive a fixed dose of 4500 IU daily. Patients between 80-100 kg will receive a fixed dose of 6000 IU daily. Patients \> 100 kg will receive a fixed dose of 8000 IU daily.
Study: NCT04976595
Drug: Natesto
Normalized name: Natesto
DrugBank: Testosterone (DB00624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal gel containing testosterone 11 mg/dose (5.5 mg/nostril) three times daily.
Study: NCT05317507
Drug: CBD oil
Normalized name: MENTHOL, UNSPECIFIED FORM 10 g in 100 g / CAMPHOR (NATURAL) 3 g in 100 g TOPICAL CREAM [ETERNAL SPIRIT BEAUTY PAINLESS WITH CBD OIL 3000]
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg
Study: NCT05317507
Drug: CBD oil
Normalized name: MENTHOL, UNSPECIFIED FORM 10 g in 100 g / CAMPHOR (NATURAL) 3 g in 100 g TOPICAL CREAM [ETERNAL SPIRIT BEAUTY PAINLESS WITH CBD OIL 3000]
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg CBD
Study: NCT05280197
Drug: liposomal bupivacaine plus free bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TAP block using liposomal bupivacaine plus free bupivacaine
Study: NCT05321706
Drug: Dapagliflozin 10 mg
Normalized name: dapagliflozin 10 MG
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will be randomized in a 1:1 fashion to receive 10 mg of oral dapagliflozin
Study: NCT04477525
Drug: Bupivacaine Injection
Normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 cc of 0.25% bupivacaine will be injected
Study: NCT04572256
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The novel use of oral montelukast offers the potential of a disease modifying treatment to prevent irreversible cartilage loss after ACL injury. 10mg of oral Montelukast will be taken daily for 6 months post surgery.
Study: NCT04947514
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (1000mg) will be administered to the raw surface of the breast prior to closure of the incisions.
Study: NCT04695704
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg oral montelukast once daily for 28 days
Study: NCT04781647
Drug: ETV
Normalized name: Metvixia
DrugBank: Methyl aminolevulinate (DB00992)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive ETV 0.5 mg tablets orally once daily
Study: NCT00003564
Drug: Isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral isotretinoin is administered every 12 hours on days 15-28 every 28 days.
Study: NCT00003564
Drug: Procarbazine Hydrochloride
Normalized name: Procarbazine Hydrochloride
DrugBank: Procarbazine (DB01168)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm I: Oral procarbazine once daily on days 1-14 every 28 days for 6 courses of combined therapy.~Arm II: Oral procarbazine once daily on days 1-14 followed by 2 weeks of rest for a total of 6 courses.
Study: NCT05196971
Drug: HS-10345 84mg
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 sprays of HS-10345 84 mg self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase
Study: NCT00002264
Drug: Cryptosporidium Immune Whey Protein Concentrate (Bovine)
Normalized name: whey protein hydrolysate
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04399343
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine hydrochloride (200 μg/2 ml) is diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour (dexmedetomidine 0.1 μg/kg/hour). The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
Study: NCT04865042
Drug: Gabapentin 300mg
Normalized name: GABAPENTIN 300MG CAP
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient will receive in addition to the usual analgesic treatment, the treatment under study: Gabapentin.~During the first 3 days of his hospitalization, an evaluation of the pain and the tolerance to the treatment will be performed.~The patient will have to take the treatment as follows:~* Day 1 (1st day of hospitalization): 1 capsule/day~* Day 2: 2 capsules/day~* Day 3: 3 capsules/day 72 hours after the first treatment, a blood test will be performed.
Study: NCT05903690
Drug: RAG-17
Normalized name: RAG-17
DrugBank: RAG-17 (DB18503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAG-17 60mg is used
Study: NCT05614518
Drug: Sodium Fluoride F-18 Injection
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each subject was given 5-10 mCi intravenously. Images were collected 90-120 min after injection.
Study: NCT05879237
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 ,1000 unit ,once daily, oral, for 1 month plus triple therapy
Study: NCT05396937
Drug: Atezolizumab Injection [Tecentriq]
Normalized name: atezolizumab Injection [Tecentriq]
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered by IV, 1200 mg on day 1 of each 21 day cycle
Study: NCT05396937
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab will be administered by IV, 10 mg/kg on day 1 of each 21 day cycle
Study: NCT05331469
Drug: NPH basal insulin titration
Normalized name: INSULIN,NPH,BEEF
DrugBank: Beef (DB10509)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparing both arms NPH basal insulin titration in reducing hba1c after 3 months
Study: NCT06371586
Drug: Albumin paclitaxel+SOX+BEV+ PD-1 monoclonal antibody therapy
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Albumin paclitaxel+SOX+BEV bi weekly neoadjuvant therapy for 6 cycles, with PD-1 monoclonal antibody therapy interspersed for 4 cycles. Review CT and gastroscopy every 3 cycles to evaluate the therapeutic effect. Patients who have been evaluated as effective after 6 cycles of treatment may consider surgery; Or continue the two-week regimen of albumin paclitaxel+bevacizumab for 3 cycles, while PD-1 monoclonal antibody for 2 cycles. Afterwards, the therapeutic effect will be evaluated, and surgery, radiotherapy, or maintenance medication treatment will be determined based on the therapeutic effect. Surgical patients begin adjuvant treatment 1-2 months after surgery based on the curative and pathological results of the surgery. Those who fail to evaluate during neoadjuvant therapy will undergo surgery or radiation therapy, or switch to a second-line systemic treatment plan.
Study: NCT04845490
Drug: Mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: Mitomycin 30mg/m2. Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
Study: NCT04845490
Drug: Lobaplatin
Normalized name: Lobaplatin
DrugBank: Lobaplatin (DB13049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lobaplatin is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: Lobaplatin 50mg/m2. Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
Study: NCT03422861
Drug: Nabilone
Normalized name: Nabilone
DrugBank: Nabilone (DB00486)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment regimen will involve nabilone capsule administration starting with 1mg BID orally first administered on POD #0. The patient will be continued on this medication for 72 hours
Study: NCT05470270
Drug: Hydroxycarbamide
Normalized name: Hydroxycarbamide
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single administration of the new dispersible form of hydroxycarbamide at the usual dose in children with sickle cell disease who are already treated with the current form of hydroxycarbamide.
Study: NCT05540743
Drug: biologic DMARDs
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: follow up the clinical response in Egyptian population to the drug
Study: NCT05819853
Drug: Semaglutide Injectable Product (Wegovy and/or Ozempic)
Normalized name: semaglutide Injectable Product
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 months of semaglutide, with dose escalation as recommended by manufacturer. Maximum dose used will be 1.7mg
Study: NCT05354713
Drug: NVP-1805
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP-1805 (80/10/20.8mg)
Study: NCT05354713
Drug: NVP-1805-R1 and NVP-1805-R2
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: coadministration of NVP-1805-R1(80mg) and NVP-1805-R2(10/20.8mg)
Study: NCT06152523
Drug: Monalizumab/MEDI5257
DrugBank: Monalizumab (DB12824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase II trial using an A'Hern design with a safety lead-in cohort to assess the safety/tolerability of the combination of monalizumab and MEDI5752 in patients with metastatic MSI/dMMR cancer